Cargando…

Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database

Background: Although ibrutinib has been widely used to treat haematological malignancies, many studies have reported associated cardiovascular events. These studies were primarily animal experiments and clinical trials. For more rational clinical drug use, a study based on post-marketing data is nec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Yi, Guo, Xiaojing, Chen, Chenxin, Chi, Lijie, Guo, Zhijian, Liang, Jizhou, Wei, Lianhui, Chen, Xiao, Ye, Xiaofei, He, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863914/ https://www.ncbi.nlm.nih.gov/pubmed/36678594 http://dx.doi.org/10.3390/ph16010098

Ejemplares similares

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
por: Chen, Chenxin, et al.
Publicado: (2021)

Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
por: Allouchery, Marion, et al.
Publicado: (2021)

Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database
por: Hu, Fangyuan, et al.
Publicado: (2021)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
por: Zhai, Yinghong, et al.
Publicado: (2021)

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
por: Zhai, Yinghong, et al.
Publicado: (2019)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database
por: Jo, Hyeong-Geun, et al.
Publicado: (2021)

Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
por: Vestergaard Kvist, Annika, et al.
Publicado: (2021)

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
por: Chiappini, Stefania, et al.
Publicado: (2023)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
por: Hoisnard, Léa, et al.
Publicado: (2022)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database
por: Nagai, Junko, et al.
Publicado: (2021)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Zhai, Yinghong, et al.
Publicado: (2022)

Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database
por: Toki, Tadashi, et al.
Publicado: (2018)

Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021
por: Wang, YanFeng, et al.
Publicado: (2022)

Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
por: Kaplan-Marans, Elie, et al.
Publicado: (2022)

Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database
por: Xu, Ye, et al.
Publicado: (2023)

Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study
por: Zhai, Yinghong, et al.
Publicado: (2022)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Local anesthetics systemic toxicity in children: analysis of the French pharmacovigilance database
por: Schweitzer-Chaput, Arnaud, et al.
Publicado: (2023)

Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada
por: Ali, Thibault B., et al.
Publicado: (2015)

Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database
por: Nakao, Satoshi, et al.
Publicado: (2021)

Current Status of Adverse Event Profile of Cyclosporine in Kidney, Stem Cell, and Heart Transplantations Using the Japanese Pharmacovigilance Database
por: Niinomi, Iku, et al.
Publicado: (2022)

Drug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database
por: Zhou, Shuang, et al.
Publicado: (2022)

Detecting associations between behavioral addictions and dopamine agonists in the Food & Drug Administration’s Adverse Event database
por: Gendreau, Katherine E., et al.
Publicado: (2014)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis
por: Scicchitano, Francesca, et al.
Publicado: (2012)

Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
por: Giofrè, Chiara, et al.
Publicado: (2013)

Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing
por: Schmider, Juergen, et al.
Publicado: (2018)

Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
por: Rodríguez, Sandra, et al.
Publicado: (2020)

A pharmacovigilance approach for assessing the occurrence of suicide-related events induced by antiepileptic drugs using the Japanese adverse drug event report database
por: Koseki, Takenao, et al.
Publicado: (2023)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database
por: Shimada, Kazuyo, et al.
Publicado: (2019)

A Pharmacovigilance Approach for Post-Marketing in Japan Using the Japanese Adverse Drug Event Report (JADER) Database and Association Analysis
por: Fujiwara, Masakazu, et al.
Publicado: (2016)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
por: Zhou, Chaozheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g402o98lkmuvugb5udg29998hm